Open AccessCancer-associated thrombosis – treatment and prevention with direct oral factor Xa inhibitors
Author(s) -
Kristína Grilusová,
Tomáš Bolek,
Ingrid Škorňová,
J. Staško,
Matej Samoš,
Marián Mokáň
Publication year - 2021
Publication title -
klinická onkologie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.204
H-Index - 13
eISSN - 1802-5307
pISSN - 0862-495X
DOI - 10.48095/ccko2021283
Subject(s) - medicine , edoxaban , apixaban , rivaroxaban , antithrombotic , intensive care medicine , venous thromboembolism , cancer , thrombosis , low molecular weight heparin , venous thrombosis , warfarin , atrial fibrillation
Venous thromboembolism (VTE) is a frequent cause of morbidity and mortality in patients with cancer. Moreover, management of VTE is frequently connected with complications, namely risk of recurrent VTE and bleeding. Low molecular weight heparins (LMWH) therapy administrated for 3-6 months is currently considered a standard for the treatment of cancer-associated VTE (CA-VTE). Direct oral factor Xa inhibitors (FXaI) apixaban, edoxaban and rivaroxaban have emerged as a new possibility for long-term antithrombotic therapy for VTE. These agents expose several advantages in individuals with cancer, and might overcome several disadvantages connected with LMWH therapy.